ONL’s experienced board of directors is actively involved in helping the company achieve its goal of protecting and improving the vision of patients with a range of retinal diseases and conditions.
Mark E. Hooper, Chairman of the Board
Mark Hooper has served as the chairman of our board of directors since November 2018. Mark has nearly 40 years of experience in public accounting, including 17 years as a partner with Ernst & Young. Currently, he serves as a founding member of Andrews, Hooper, Pavlik PLC, a regional CPA firm in the state of Michigan. During his career, Mark has accumulated broad professional expertise which ranges from advanced tax matters for business and publicly traded corporations to estate and individual tax planning.
An active member of the business community, Mark serves on the board of directors of the Auto Owners Insurance Group and Capital Community Angels, in addition to ONL Therapeutics. He also holds the position of treasurer of the Capital Community Angels and has served as chair of a number of community boards, providing guidance to groups ranging from the Capital Region Community Foundation to the Broad College of Business Alumni Board at Michigan State University.
David Esposito, President and Chief Executive Officer
David Esposito is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers.
David is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.
He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) for in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division.
David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.
David Zacks, M.D., Ph.D., Co-Founder and Chief Science Officer
Dr. Zacks is an associate professor of ophthalmology and a clinician-scientist at the University of Michigan, Kellogg Eye Center. For over the past 15 years his research has focused on the molecular regulatory mechanisms controlling photoreceptor death or survival in retinal disease. Dr. Zacks is a pioneer and recognized thought leader in the field of retinal neuroprotection and photoreceptor cells physiology. He has demonstrated that the Fas pathway is largely responsible for cell death and has discovered unique molecules that block the Fas receptor and preserve photoreceptors.
A recognized expert in the study of retinal detachment, Dr. Zacks has received numerous honors for his work, including the Macula Society’s W. Richard Green Lecture and Award in 2011. He earned his M.D. and Ph.D. degrees at Albert Einstein College of Medicine and completed his residency in ophthalmology and fellowship in vitreoretinal surgery at Massachusetts Eye and Ear Infirmary of Harvard Medical School.
Felicia D. David-Visser, CFA
Felicia D. David-Visser is a Senior Manager of Investments at the University of Michigan Investment Office with current responsibilities in the credit and income oriented strategies across traditional and private equity structures. In addition, Felicia is managing the Michigan Investment in New Technology Startups (“MINTS”) initiative as part of the University’s Venture Capital portfolio. Felicia has been working at the University of Michigan’s Investment Office since 2000 and has been involved in investment activities in the University’s Endowment and Working Capital portfolios ranging from absolute return and fixed income to equities.
Prior to joining the University, Ms. David-Visser was employed by Royal & SunAlliance Insurance Group Plc and focused on asset/liability management and asset modeling.
Ms. David-Visser earned a B.S. in Mathematics from the University of Michigan, Ann Arbor, and a Master of Science in Computational Finance & Risk Management, Department of Applied Mathematics, from the University of Washington, Seattle. She is a Chartered Financial Analyst (CFA).
M. Christine Gibbons
Chris has over thirty years of financial management, fundraising and operating experience and for the past twenty years has been deeply involved with early-stage emerging technology companies, both as an investor and part of entrepreneurial management teams. Together with other founders, she has raised over $80 million in start-up capital to launch and support fourteen new ventures.
Chris is currently Co-Founder/Chief Operating Officer of HistoSonics, Inc., a medical device company developing a non-invasive, image-guided, highly precise tissue ablation technology for cost effective treatments of significant cancers and diseases. She has served the company in various roles including president, chief operating officer and interim chief executive officer. Prior to HistoSonics, she has held various leadership roles in entrepreneurial ventures including Executive in Residence (EIR) for Venture Investors, LLC, chief financial officer for Sensicore, a company with lab-on-a-chip sensor products (acquired by a division of GE), VP of Finance for Ardesta, an investor in “small-tech” opportunities and Partner and CFO of Seaflower Ventures, a venture capital firm focused on early-stage biomedical opportunities.
Chris serves as an Advisor to Apjohn Ventures Fund LP, is a member of UM’s Venture Center Council and is an advisory board member of Michigan State University’s Center for Venture Capital, Private Equity and Entrepreneurial Finance. She was on the Technical Oversight Committee for the Coulter Program at the University of Michigan (UM) from 2008 – 2016 and serves as a guest lecturer at Michigan State University’s Business School. Chris holds an MBA from Wayne State University and a BA from Michigan State University.